The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies
Open accessAbstract
BACKGROUND Guidelines advise multiparametric magnetic resonance imaging (mpMRI) before repeat biopsy in patients with negative systematic biopsy (SB) and a suspicion of prostate cancer (PCa), enabling MRI targeted biopsy (TB). No consensus exists regarding which of the three available techniques of TB should be preferred. OBJECTIVE To compare detection rates of overall PCa and clinically significant PCa (csPCa) for the three MRI-based TB techniques. DESIGN, SETTING, AND PARTICIPANTS Multicenter randomised controlled trial, including 665 men with prior negative SB and a persistent suspicion of PCa, conducted between 2014 and 2017 in two nonacademic teaching hospitals and an academic hospital. INTERVENTION All patients underwent 3-T mpMRI evaluated with Prostate Imaging Reporting and Data System (PIRADS) version 2. If imaging demonstrated PIRADS ≥3 lesions, patients were randomised 1:1:1 for one TB technique: MRI-transrectal ultrasound (TRUS) fusion TB (FUS-TB), cognitive registration TRUS TB (COG-TB), or in-bore MRI TB (MRI-TB). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Primary (overall PCa detection) and secondary (csPCa detection [Gleason score ≥3+4]) outcomes were compared using Pearson chi-square test. RESULTS AND LIMITATIONS On mpMRI, 234/665 (35%) patients had PIRADS ≥3 lesions and underwent TB. There were no significant differences in the detection rates of overall PCa (FUS-TB 49%, COG-TB 44%, MRI-TB 55%, p=0.4). PCa detection rate differences were -5% between FUS-TB and MRI-TB (p=0.5, 95% confidence interval [CI] -21% to 11%), 6% between FUS-TB and COG-TB (p=0.5, 95% CI -10% to 21%), and -11% between COG-TB and MRI-TB (p=0.17, 95% CI -26% to 5%). There were no significant differences in the detection rates of csPCa (FUS-TB 34%, COG-TB 33%, MRI-TB 33%, p>0.9). Differences in csPCa detection rates were 2% between FUS-TB and MRI-TB (p=0.8, 95% CI -13% to 16%), 1% between FUS-TB and COG-TB (p>0.9, 95% CI -14% to 16%), and 1% between COG-TB and MRI-TB (p>0.9, 95% CI -14% to 16%). The main study limitation was a low rate of PIRADS ≥3 lesions on mpMRI, causing underpowering for primary outcome. CONCLUSIONS We found no significant differences in the detection rates of (cs)PCa among the three MRI-based TB techniques. PATIENT SUMMARY In this study, we compared the detection rates of (aggressive) prostate cancer among men with prior negative biopsies and a persistent suspicion of cancer using three different techniques of targeted biopsy based on magnetic resonance imaging. We found no significant differences in the detection rates of (aggressive) prostate cancer among the three techniques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,091
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.052 · Cited by 2,951
Self-citationEpstein, J. I., Allsbrook, W. C., Amin, M. B., & Egevad, L. L. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000173646.99337.b1 · Cited by 2,763
ESUR prostate MR guidelines 2012
Barentsz, J. O., Richenberg, J., Clements, R., Choyke, P., Verma, S., Villeirs, G., Rouviere, O., Logager, V., & Fütterer, J. J. (2012) · European Radiology · doi:10.1007/s00330-011-2377-y · Cited by 2,438
Self-citationCONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., & Moher, D. (2011) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.09.004 · Cited by 1,044
Katayama, H., Kurokawa, Y., Nakamura, K., Ito, H., Kanemitsu, Y., Masuda, N., Tsubosa, Y., Satoh, T., Yokomizo, A., Fukuda, H., et al. (2016) · Surgery Today · doi:10.1007/s00595-015-1236-x · Cited by 782
Schoots, I. G., Roobol, M. J., Nieboer, D., Bangma, C. H., Steyerberg, E. W., & Hunink, M. G. M. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.037 · Cited by 687
Cited by
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Multiparametric MRI for prostate cancer diagnosis: current status and future directions
Stabile, A., Giganti, F., Rosenkrantz, A. B., Taneja, S. S., Villeirs, G., Gill, I. S., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0212-4 · Cited by 398
Metadata
- Authors
- Wegelin, O., Exterkate, L., van der Leest, M., Kummer, J. A., Vreuls, W., de Bruin, P. C., Bosch, J. L. H. R., Barentsz, J. O., Somford, D. M., & van Melick, H. H. E.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 75
- Issue
- 4
- Pages
- 582-590
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2902322634
- Cited by
- 291
- References
- 20
- FWCI
- 20.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. https://app.cochat.ai/papers/10.1016/j.eururo.2018.11.040
- The paper
- Wegelin, O., Exterkate, L., van der Leest, M., Kummer, J. A., Vreuls, W., de Bruin, P. C., Bosch, J. L. H. R., Barentsz, J. O., Somford, D. M., & van Melick, H. H. E. (2019). The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. European Urology. https://doi.org/10.1016/j.eururo.2018.11.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.